FXR and PXR: Potential therapeutic targets in cholestasis

This publication has 143 references indexed in Scilit:

• PXR Prevents Cholesterol Gallstone Disease by Regulating Biosynthesis and Transport of Bile Salts
  Gastroenterology, 2011
• Role of nuclear receptor SHP in metabolism and cancer
  Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2010
• High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis #
  Hepatology, 2009
• Bile acid signaling pathways increase stability of Small Heterodimer Partner (SHP) by inhibiting ubiquitin–proteasomal degradation
  Genes & Development, 2009
• ATP8B1 Deficiency Disrupts the Bile Canalicular Membrane Bilayer Structure in Hepatocytes, But FXR Expression and Activity Are Maintained
  Gastroenterology, 2009
• The membrane protein ATPase class I type 8B member 1 signals through protein kinase C zeta to activate the farnesoid X receptor
  Hepatology, 2008
• Hepatoprotective role of PXR activation and MRP3 in cholic acid‐induced cholestasis
  British Journal of Pharmacology, 2007
• Benefit of farnesoid X receptor inhibition in obstructive cholestasis
  Proceedings of the National Academy of Sciences, 2006
• Guggulsterone antagonizes farnesoid X receptor induction of bile salt export pump but activates pregnane X receptor to inhibit cholesterol 7α-hydroxylase gene
  Biochemical and Biophysical Research Communications, 2003
• Regulation of cholesterol 7α-hydroxylase gene ( CYP7A1 ) transcription by the liver orphan receptor (LXRα)
  Gene, 2001